Pembrolizumab and GM-CSF in Biliary Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 6, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Biliary Cancer

Interventions

DRUG

Pembrolizumab

200 mg given intravenously (IV)

DRUG

Sargramostim

250 µg given subcutaneously (SC)

Trial Locations (1)

University of California San Francisco, San Francisco

All Listed Sponsors

collaborator

American Society of Clinical Oncology

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Robin Kate Kelley

OTHER

NCT02703714 - Pembrolizumab and GM-CSF in Biliary Cancer | Biotech Hunter | Biotech Hunter